Background and objective Once the malignant pleural or peritoneal effusion is developed it is difficult to control.This report presents a new method for controlling the malignant effusions.Methods Forty-eight patients...Background and objective Once the malignant pleural or peritoneal effusion is developed it is difficult to control.This report presents a new method for controlling the malignant effusions.Methods Forty-eight patients,29 males and 19 females with an average age of 61.2 years old,who were satisfied with the study inclusion criteria,were recruited in this study.Twenty-seven and 21 patients had a malignant pleural and peritoneal effusion,respectively.After draining most of fluids,these patients received intra-cavity infusion of rAd-p53 once per week for 4 weeks,at dose of 2×1012 viral particles(VP) diluted into 200 mL of saline solution for pleural effusions,and 4×1012 VP diluted into 500 mL of saline solution for peritoneal effusions.Results Participants were followed up for a median time of 13.6 month.A total of 11 cases,7 with pleural effusions and 4 with peritoneal effusions achieved a complete response(CR),and 20 cases(12 pleural effusions and 8 peritoneal effusions) had a partial response(PR).The overall response rate is 64.6%.Patients' quality of life,assessed by using Karnofsky performance scale(KPS) scores,was improved by an average of 26.4.The one-year of overall survival rate was 54.2% with a median survival time of 12.5 months.There were no serious side effects observed except for self-limited fever found in 79.8% of the cases.Conclusions Intra-cavity infusion of rAd-p53 is an effective and safe treatment for the patients with malignant pleural or peritoneal effusions,especially for those patients who can't tolerate the standard treatments.展开更多
目的探讨Survivin、胰岛素样生长因子ⅡmRNA结合蛋白3(insulin-like growth factorⅡmRNA-binding protein 3,IMP3)及Claudin1在浆膜腔积液细胞蜡块中的表达及临床意义。方法收集我院病理科2017年2月~2021年11月行免疫组化检查且临床资...目的探讨Survivin、胰岛素样生长因子ⅡmRNA结合蛋白3(insulin-like growth factorⅡmRNA-binding protein 3,IMP3)及Claudin1在浆膜腔积液细胞蜡块中的表达及临床意义。方法收集我院病理科2017年2月~2021年11月行免疫组化检查且临床资料齐全的浆膜腔积液细胞块95例,其中恶性84例,良性11例(对照组)。应用免疫组化方法检测浆膜腔积液细胞蜡块中Survivin、IMP3及Claudin1蛋白的表达情况,并对比分析其在良恶性浆膜腔积液以及不同恶性肿瘤中的差异。结果恶性胸膜腔积液病例中胸腔积液53例,腹腔积液31例。肺腺癌41例,消化系统腺癌25例,卵巢恶性肿瘤9例,其他恶性肿瘤9例。与对照组相比,肺腺癌组及消化系统腺癌组IMP3的表达差异具有统计学意义(P<0.05),消化系统腺癌组Claudin1的表达差异具有统计学意义(P<0.05),其他组别Survivin、IMP3及Claudin1的表达与对照组相比差异均无统计学意义(P>0.05)。结论IMP3及Claudin1在恶性浆膜腔积液判断是否为消化系统腺癌来源时具有鉴别意义,IMP3在肺腺癌来源具有鉴别意义。展开更多
文摘Background and objective Once the malignant pleural or peritoneal effusion is developed it is difficult to control.This report presents a new method for controlling the malignant effusions.Methods Forty-eight patients,29 males and 19 females with an average age of 61.2 years old,who were satisfied with the study inclusion criteria,were recruited in this study.Twenty-seven and 21 patients had a malignant pleural and peritoneal effusion,respectively.After draining most of fluids,these patients received intra-cavity infusion of rAd-p53 once per week for 4 weeks,at dose of 2×1012 viral particles(VP) diluted into 200 mL of saline solution for pleural effusions,and 4×1012 VP diluted into 500 mL of saline solution for peritoneal effusions.Results Participants were followed up for a median time of 13.6 month.A total of 11 cases,7 with pleural effusions and 4 with peritoneal effusions achieved a complete response(CR),and 20 cases(12 pleural effusions and 8 peritoneal effusions) had a partial response(PR).The overall response rate is 64.6%.Patients' quality of life,assessed by using Karnofsky performance scale(KPS) scores,was improved by an average of 26.4.The one-year of overall survival rate was 54.2% with a median survival time of 12.5 months.There were no serious side effects observed except for self-limited fever found in 79.8% of the cases.Conclusions Intra-cavity infusion of rAd-p53 is an effective and safe treatment for the patients with malignant pleural or peritoneal effusions,especially for those patients who can't tolerate the standard treatments.
文摘目的探讨Survivin、胰岛素样生长因子ⅡmRNA结合蛋白3(insulin-like growth factorⅡmRNA-binding protein 3,IMP3)及Claudin1在浆膜腔积液细胞蜡块中的表达及临床意义。方法收集我院病理科2017年2月~2021年11月行免疫组化检查且临床资料齐全的浆膜腔积液细胞块95例,其中恶性84例,良性11例(对照组)。应用免疫组化方法检测浆膜腔积液细胞蜡块中Survivin、IMP3及Claudin1蛋白的表达情况,并对比分析其在良恶性浆膜腔积液以及不同恶性肿瘤中的差异。结果恶性胸膜腔积液病例中胸腔积液53例,腹腔积液31例。肺腺癌41例,消化系统腺癌25例,卵巢恶性肿瘤9例,其他恶性肿瘤9例。与对照组相比,肺腺癌组及消化系统腺癌组IMP3的表达差异具有统计学意义(P<0.05),消化系统腺癌组Claudin1的表达差异具有统计学意义(P<0.05),其他组别Survivin、IMP3及Claudin1的表达与对照组相比差异均无统计学意义(P>0.05)。结论IMP3及Claudin1在恶性浆膜腔积液判断是否为消化系统腺癌来源时具有鉴别意义,IMP3在肺腺癌来源具有鉴别意义。
